KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic.
HIV-1 protease inhibitors containing allophenylnorstatine [Apns; (2S,3S)-3-amino-2-hydroxy-4-phenylbutyric acid]-Pro (syn diastereomer) as a transition-state mimic were established to be potent and highly selective. Z-Asn-Apns-Pro-NHBut (KNI-102) is the only tripeptide exhibiting substantial anti-HIV activity and may be of minimum size for potent, selective inhibition of HIV protease. Ready availability due to its simple chemical structure and stability should make it valuable for studies of the development of metabolically stable anti-AIDS drugs.
Mimoto
T
T
Department of Medicinal Chemistry, Kyoto Pharmaceutical University, Japan.
Imai
J
J
Tanaka
S
S
Hattori
N
N
Kisanuki
S
S
Akaji
K
K
Kiso
Y
Y
D000595:Amino Acid Sequence; D017320:HIV Protease Inhibitors; D008968:Molecular Conformation; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology*; D010654:Phenylbutyrates / Q000737:chemistry*
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D010654:Phenylbutyrates; C073513:KNI 102; C034940:3-amino-2-hydroxy-4-phenylbutanoic acid